Get started
CVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORD (USD)CC

CVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORD (USD)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

CVSD trade ideas

CVS Health Plunges to 3-Year Low for the First TimeCVS Health Corporation ( NYSE:CVS ) stock price nosedives to its lowest level in three years, sending shockwaves through the market. The pharmacy chain's dismal performance in the first quarter of 2024 has rattled investors, with shares plummeting over 12% in premarket trading. The root cause of CVS Health's ( NYSE:CVS ) precipitous decline lies in its underwhelming Q1 earnings report, which fell short of market expectations on multiple fronts. Despite reporting a revenue of $88.44 billion, reflecting a 3.7% increase year-over-year, the figure failed to meet analysts' projections of $89.33 billion. Similarly, net income and diluted earnings per share (EPS) witnessed a significant decline compared to the previous year, with profits plummeting from $2.14 billion to $1.12 billion and EPS dropping from $1.65 to 88 cents. The downward spiral in CVS Health's fortunes can be attributed to a confluence of factors, chief among them being the slashing of its 2024 profit forecast. The company revised its adjusted EPS outlook downward to at least $7.00, down from the initial projection of at least $8.30. This drastic revision stems from mounting medical costs incurred by its insurance unit, driven by a surge in medical procedures that were postponed during the pandemic. As patients opt to undergo delayed treatments, CVS's insurance divisions are bearing the brunt, impacting the company's bottom line. While there was a faint glimmer of hope in the form of a slight sales increase in its pharmacy and consumer wellness division, with sales rising almost 3% to $28.73 billion, it failed to offset the broader disappointment. The challenges facing CVS Health ( NYSE:CVS ) extend beyond financial metrics, with the company grappling with workforce reductions and the loss of high-profile clients like Tyson Foods. The tumultuous environment has prompted NYSE:CVS to revise its full-year EPS guidance downward to at least $5.64, down from the previous estimate of at least $7.06. Despite the gloomy outlook, CEO Karen Lynch remains steadfast in her optimism about the company's long-term prospects. She asserts that while CVS faces near-term challenges, its fundamental strengths and strategic initiatives position it for sustained growth in the future.
NShort
by DEXWireNews
CVS testing breakout resistanceCVS Health Corp (CVS) presently testing breakout resistance, able to contain weekly buying pressures. From here (CVS) can fall back to recent lows, eliciting losses of 15% over the following 1-2 months. A settlement below a near-term channel bottom would accelerate this potential selloff. Inversely, if a settlement above breakout resistance occurs, this would place (CVS) in a a buy signal where gains of 15% would be expected within 2-3 months, and 20% over the following 3-5 months.
N
by SpecialeAnalysis
Support And Resistance Lines Are Not Real: Prove Me WrongIn this video, I draw random lines on the chart to prove a point. I think we need to ask ourselves the following questions to become better traders: How will I define support and resistance consistently ? How will I use support and resistance in my trading? Do I need support and resistance in my trading? Is support and resistance a reliable measure for markets? Are the lines that I have been drawing for so long actually meaningful?
NEducation
by JoeRodTrades
2
Analysis of CVS Stock Trends: A Parabolic Turn on the HorizonFashionable Analysis of CVS Stock Trends: A Parabolic Turn on the Horizon Introduction: In the realm of financial fashion, CVS stock is set to make a stylish entrance with a parabolic turn, showcasing a strong formation on the 4D timeframe. This trend is marked by the elegant falling wedge pattern and the chic double bottom overlapping patterns, following a dose of impactful news related to drug patents. Technical Analysis - CVS Stock: The 4D timeframe reveals the graceful formation of a falling wedge pattern, signifying a poised parabolic turn in CVS stock. This pattern, complemented by double bottom overlapping formations, is a testament to the stock's resilience, especially against the backdrop of recent drug patent news highlighted on CNBC ( www.cnbc.com ). Price Targets and Corrections: The first take profit target stands confidently at $76.78, offering investors a lucrative moment to capitalize on the impending parabolic turn. Following this peak, a correction to approximately $71.07 is expected, providing a brief pause for market adjustments. Strategic Entry and Second Take Profit Target: Wise investors can strategically enter the market around $71.07, anticipating a second take profit target at a stylish $82.44. This forecasted move aligns with the rhythm of the stock's recent patterns, emphasizing the importance of timing in the world of financial fashion. Historical Elegance: Tracing CVS stock's journey since April 2019, a period marking the middle of the pandemic, unveils a remarkable rally. The stock gracefully formed a strong falling wedge pattern on the 4Day timeframe, echoing a sense of resilience and adaptability. The rally continued, reaching its peak around February 01, 2022, before gracefully correcting until October 25, 2023. Future Projections: As the music of the market plays on, further continuation of this trend is expected. The forecasted trajectory anticipates a new level of elegance for CVS stock by the end of 2024, reaching a poised $106.97. This future projection exudes confidence and sets the stage for CVS to make a bold statement in the financial fashion world. In the intricate dance of stocks and patterns, CVS is poised to captivate investors with its upcoming parabolic turn and a tale of resilience, gracefully crafted on the canvas of market trends.
NLong
by wikitrades
CVS Health Lays out Changes That May Save some Customers MoneyCVS Health is introducing changes to how its prescription drug pricing model works, and that could lead to some savings for customers starting next year. The health care giant said Tuesday that it will roll out a new reimbursement model designed to make costs more predictable at the drugstore counter. The company will start offering it next year to some third-party cash discount card administrators. Cash discount cards like those offered by GoodRx can give customers a price break on out-of-pocket costs for some prescriptions, depending on the person’s coverage and the drug. CVS Health drugstores will start using the company’s new Cost Vantage model more broadly in 2025. It is designed to make drug costs more transparent. It involves a formula based on the cost of the drug, a set markup and then a fee for filling the prescription. CVS Health runs one of the nation’s largest drugstore chains and a large pharmacy benefit management business that operates prescription drug coverage for big clients like insurers and employers. It also sells health insurance through its Aetna arm, and the company has been providing a growing amount of care through its drugstores and clinics. The company also announced on Tuesday a 10% hike in its quarterly dividend and laid out its forecast for next year. CVS Health expects adjusted earnings of at least $8.50 per share. It also forecasts total revenue of at least $366 billion. Analysts expect earnings of $8.51 per share on $344.5 billion in revenue, according to FactSet. Price Momentum CVS is trading near the bottom of its 52-week range and near its 200-day simple moving average. Investors have been pushing the share price lower, but the stock might be losing some downward momentum. This is a neutral sign for the stock's future value.
NLong
by DEXWireNews
Trading idea for CVS Health Corp. stocks (06/12/2023)CVS Health Corp. revised its forecast for revenue in 2024 upward to 366 billion USD. In addition, the issuer announced an increase in dividend payments by 9.9%. Such moves boost the attractiveness of the company's shares; moreover, the inevitable emergence of new diseases promises increased sales for CVS Health. So, today, we decided to look at the CVS Health Corp. (NYSE: CVS) stock chart. On the D1 timeframe, support has formed at 66.01, with resistance at 71.34. A breakthrough of resistance could lead to the beginning of a medium-term uptrend. On the H1 timeframe, a breakout from the 71.34 level could set the target for a price increase to 77.29, while in the medium term, it could hover around 84.90, influenced by the "Santa Claus rally". — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
N
by RoboMarkets
CVS Health Higher on Dividend Boost, Solid 2024 Revenue ForecastCVS Health, facing the potential for deeper industry consolidation, lifted its 2024 sales forecast and boosted its quarterly dividend. CVS Health (CVS) - shares jumped higher Tuesday after the group boosted its quarterly dividend, while forecasting stronger-than-expected 2024 sales. The health-care and drugstore group looks to streamline its broader business amid renewed talk of consolidation in the health-insurance sector. CVS sees overall revenue of at least $366 billion next year, firmly ahead of the LSEG forecast of around $346 billion, with adjusted profit coming in at around $8.51 per share. The group also reiterated its 2023 forecasts for adjusted profit in the region of $8.50 to $8.70 a share as well as cash flows from its overall business to come in between $12.5 billion to $13.5 billion. In addition, CVS lifted its quarterly dividend by 10%, to 66.5 cents a share, payable Feb. 1 to holders of record Jan. 22. CVS shares were marked 2.44% higher in premarket trading to indicate an opening bell price of $70.18 each, a move that would nudge the stock into positive territory for the past six months. CVS rebrands health services division The Woonsocket, Rhode Island-based group, one of the country's biggest pharmacy-benefits managers, also unveiled plans to rebrand its Health Services segment under the name CVS Healthspire. That division will include a host of its current units, including Oak Street Health, Signify and its MinuteClinic. "Delivering care in a more integrated way — especially for complex patients with chronic health conditions — improves health outcomes and the patient experience," said Oak Street Health's interim president, Mike Pykosz. Technical Analysis CVS is trading near the bottom of its 52-week range and below its 200-day simple moving average. Investors have been pushing the share price lower, and the stock still appears to have downward momentum. This is a negative sign for the stock's future value.
NLong
by DEXWireNews
Current Developments on CVS chart can make for opportunityHi guys! This is a Technical analysis on CVS Health Corporation (CVS) on the 3 day timeframe. We discuss some Current developments on CVS, which maybe pointing to signs of potential opportunity to invest/ hold CVS. We've had a deathcross that has brought us down more than 38%. Which has lead us to a critical support trendline that has acted as support since March 2019. We recently bounced from this trendline with a BULLISH ENGULFING candle print We have from this support line bounced up to reach the 21 EMA Current price action is attempting to establish support on 21 EMA. MACD has crossed Bullish with Green bars printing. BUT also remember that we have resistance above us from the 50 SMA. We are also in an established DOWNTREND from the Deathcross. Until proven otherwise so we have to pay attention for signs of trend change. Key area is around the 2 moving averages. We need to establish support on 21 EMA. We have to also see how we react with the 50 SMA. If we get ABOVE 50 SMA and maintain support, it is likely we print a GOLDEN CROSS, leading to BUY pressure to come in. This could be the necessary catalyst for trend change. Another hint in an attempt to trend change is the 21 EMA flattening out, beginning to show signs of a curvature to upside. Now lets Look left to find evidence of previous patterns in the Moving average interactions, Support line interaction and MACD. Our first time interacting with the SUpport line, we had many touches, before printing a GOLDEN CROSS. ALong with MACD CROSS ABOVE 0 level, we had a 48% Uptrend. Our 2nd interaction with SUpport line, we experienced a fakeout on the 1st touch. MACD could NOT move ABOVE 0 level. The 2nd touch of support line, had the GOLDEN CROSS and the MACD cross ABOVE 0 level. This lead to an extended Bull run for CVS with gains of 100%. Keep this in mind. Look for similar pattern in our current price action. If we see a Golden Cross with MACD crossing ABOVE 0 level. This would mean an UPTREND is probable. But dont discount the possibility of a fakeout. We can always have another attempt to test support on support line. Watch closely for these to develop in our current price action. Best opportunity to invest would be after Golden cross has been established with confirmed MACD cross Above 0 level in my opinion. __________________________________________________________________________________ Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again. Stay tuned for more updates on CVS in the near future. If you have any questions, do reach out. Thank you again. DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
NLong
by SafofAllTrades
1
$CVS Setting Up as Undercut & Reverse (U&R)?NYSE:CVS released news today that Blue Cross of CA will no longer use them for prescription management. As a result, we have a big sell-off which may be overdone. TBD. I am looking at this as a potential U&R. I have it measured against the most recent lowest low of $66.34. I have an alert set crossing over $66.40. If that triggers and on a 5-minute chart and it looks bullish I’ll enter with a stop just below $66.34. This is a higher risk trade; however, risk can be minimized by using a stop just under that lowest low. Let’s see what happens. It may just continue to fall. I do not know. Ideas, not investing / trading advice. Comments welcome. Thanks for looking.
N
by jaxdog